journal article·2020-01-08

Silica-Coated Nanoparticles with a Core of Zinc, l-Arginine, and a Peptide Designed for Oral Delivery

Delyan Hristov, Fiona McCartney, Jason Beirne, Eugene Mahon, Stephanie Reid, Sourav Bhattacharjee, Geraldine Penarier, Ulrich Werner, Didier Bazile, David J. Brayden

Publisher page

Abstract

Nanoparticle constructs for oral peptide delivery at a minimum must protect and present the peptide at the small intestinal epithelium in order to achieve oral bioavailability. In a reproducible, scalable, surfactant-free process, a core was formed with insulin in ratios with two established excipients and stabilizers, zinc chloride and l-arginine. Cross-linking was achieved with silica, which formed an outer shell. The process was reproducible across several batches, and physicochemical characterization of a single batch was confirmed in two independent laboratories. The silica-coated nanoparticles (SiNPs) entrapped insulin with high entrapment efficiency, preserved its structure, and released it at a pH value present in the small intestine. The SiNP delivered insulin to the circulation and reduced plasma glucose in a rat jejunal instillation model. The delivery mechanism required residual l-arginine in the particle to act as a permeation enhancer for SiNP-released insulin in the jejunum. The synthetic process was varied in terms of ratios of zinc chloride and l-arginine in the core to entrap the glucagon-like peptide 1 analogue, exenatide, and bovine serum albumin. SiNP-delivered exenatide was also bioactive in mice to some extent following oral gavage. The process is the basis for a platform for oral peptide and protein delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Protein purification and stability

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Sanofi Recherche & Développement, PSO/LGCR, Bâtiment BLP, rue du Pr Blayac, 34184 Montpellier Cedex 4, France

Sanofi-Aventis Deutschland GmbH. Industriepark Höchst, K703 65926 Frankfurt, Germany

Sanofi Recherche & Développement, CMC External Innovation, 82, avenue Raspail, 94250 Gentilly Cedex, France

Funding

FP7 Nanosciences, Nanotechnologies, Materials and new Production Technologies · Science Foundation Ireland

References (59)

Show source-provided references
1. 10.3390/molecules2404080910.3390/molecules24040809 ↗
2. 10.1016/j.addr.2016.01.01010.1016/j.addr.2016.01.010 ↗
3. 10.1111/jan.1381810.1111/jan.13818 ↗
4. 10.1530/eje-15-104210.1530/eje-15-1042 ↗
5. 10.1111/dom.1297710.1111/dom.12977 ↗
6. 10.1111/jphp.1285210.1111/jphp.12852 ↗
7. 10.1080/21688370.2016.115680410.1080/21688370.2016.1156804 ↗
8. 10.1016/s2213-8587(18)30372-310.1016/s2213-8587(18)30372-3 ↗
9. 10.1001/jama.2019.294210.1001/jama.2019.2942 ↗
10. 10.1021/acs.chemrev.6b0083810.1021/acs.chemrev.6b00838 ↗
11. 10.1016/j.addr.2016.02.00410.1016/j.addr.2016.02.004 ↗
12. 10.1038/nrd.2018.18310.1038/nrd.2018.183 ↗
13. 10.1126/scitranslmed.aar704710.1126/scitranslmed.aar7047 ↗
14. 10.1210/jc.2014-411310.1210/jc.2014-4113 ↗
15. 10.1080/21688370.2016.117682210.1080/21688370.2016.1176822 ↗
16. 10.1016/j.jconrel.2014.10.02610.1016/j.jconrel.2014.10.026 ↗
17. 10.1016/j.ijpharm.2018.01.01810.1016/j.ijpharm.2018.01.018 ↗
18. 10.1016/j.jconrel.2012.11.00510.1016/j.jconrel.2012.11.005 ↗
19. 10.1016/j.jconrel.2017.02.02410.1016/j.jconrel.2017.02.024 ↗
20. 10.1016/j.jconrel.2018.03.00410.1016/j.jconrel.2018.03.004 ↗
21. 10.1016/j.jconrel.2018.10.02210.1016/j.jconrel.2018.10.022 ↗
22. 10.1016/j.ejpb.2018.09.02310.1016/j.ejpb.2018.09.023 ↗
23. 10.1016/s0140-6736(76)91209-510.1016/s0140-6736(76)91209-5 ↗
24. 10.2337/diab.37.2.24610.2337/diab.37.2.246 ↗
25. 10.1126/scitranslmed.300704910.1126/scitranslmed.3007049 ↗
26. 10.2217/nnm.16.4310.2217/nnm.16.43 ↗
27. 10.1016/j.drudis.2012.06.01410.1016/j.drudis.2012.06.014 ↗
28. 10.1016/j.colsurfb.2017.04.02410.1016/j.colsurfb.2017.04.024 ↗
29. 10.1016/j.ejpb.2015.03.02710.1016/j.ejpb.2015.03.027 ↗
30. 10.1016/j.ijpharm.2014.07.04910.1016/j.ijpharm.2014.07.049 ↗
31. 10.1016/j.ijpharm.2013.06.05110.1016/j.ijpharm.2013.06.051 ↗
32. 10.3389/fchem.2019.0029010.3389/fchem.2019.00290 ↗
33. 10.3390/pharmaceutics11030129.10.3390/pharmaceutics11030129. ↗
34. 10.1080/17425247.2018.150325010.1080/17425247.2018.1503250 ↗
35. 10.1016/j.colsurfb.2018.04.06410.1016/j.colsurfb.2018.04.064 ↗
36. 10.1021/acs.jpcb.8b0655710.1021/acs.jpcb.8b06557 ↗
37. 10.1016/j.ijpharm.2017.01.06610.1016/j.ijpharm.2017.01.066 ↗
38. 10.1016/j.ejpb.2018.10.01310.1016/j.ejpb.2018.10.013 ↗
39. 10.1016/j.jconrel.2019.08.00810.1016/j.jconrel.2019.08.008 ↗
40. 10.1016/j.jconrel.2008.09.09110.1016/j.jconrel.2008.09.091 ↗
41. 10.1016/j.addr.2011.06.01110.1016/j.addr.2011.06.011 ↗
42. 10.1016/j.xphs.2017.11.01510.1016/j.xphs.2017.11.015 ↗
43. 10.1021/acs.jpclett.8b0278510.1021/acs.jpclett.8b02785 ↗
44. 10.1016/j.colsurfb.2018.02.00410.1016/j.colsurfb.2018.02.004 ↗
45. 10.1021/ar300098610.1021/ar3000986 ↗
46. 10.1039/c6nr09331k10.1039/c6nr09331k ↗
47. 10.1016/j.addr.2009.09.00610.1016/j.addr.2009.09.006 ↗
48. 10.1016/j.jconrel.2016.10.00210.1016/j.jconrel.2016.10.002 ↗
49. 10.1038/s41565-018-0246-410.1038/s41565-018-0246-4 ↗
50. 10.1007/s11095-019-2578-710.1007/s11095-019-2578-7 ↗
51. 10.1093/oxfordjournals.jbchem.a00326110.1093/oxfordjournals.jbchem.a003261 ↗
52. 10.1016/j.addr.2016.06.00510.1016/j.addr.2016.06.005 ↗
53. 10.1016/j.ijpharm.2017.07.00110.1016/j.ijpharm.2017.07.001 ↗
54. 10.1016/j.xphs.2016.09.02910.1016/j.xphs.2016.09.029 ↗
55. 10.1016/j.jconrel.2016.06.01610.1016/j.jconrel.2016.06.016 ↗
56. 10.1016/j.addr.2016.07.00710.1016/j.addr.2016.07.007 ↗
57. 10.1016/j.jconrel.2014.10.02610.1016/j.jconrel.2014.10.026 ↗
58. 10.1016/j.actbio.2019.03.01010.1016/j.actbio.2019.03.010 ↗
59. 10.1038/s41598-019-39107-310.1038/s41598-019-39107-3 ↗